Affini-T Therapeutics

📍 Watertown, United States👥 91 employees💰 Last funded Mar 2022
Biotechnology Research🌐 affinittx.com
Website LinkedIn
Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Affini-T Therapeutics?
Affini-T Therapeutics has 1 investors on record on gritt.io.
When did Affini-T Therapeutics last raise funding?
The most recent investment in Affini-T Therapeutics recorded on gritt.io was in March 2022.
What industry is Affini-T Therapeutics in?
Affini-T Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Affini-T Therapeutics based?
Affini-T Therapeutics is headquartered in Watertown, United States.